Effect of rosiglitazone, pioglitazone, troglitazone, and prototypical inducers on mRNA in primary cultures of human hepatocytes
| Treatment | CYP3A4 | CYP2B6 |
|---|---|---|
| Rifampin 50 μM | 14.62 ± 6.12 | 2.67 ± 0.24 |
| Dexamethasone 10 μM | 5.47 ± 1.00 | No change |
| Phenobarbital 1 mM | 8.10 ± 1.10 | 6.46 ± 1.80 |
| Rosiglitazone 10 μM | 1.87 ± 0.23 | No change |
| Rosiglitazone 50 μM | 5.43 ± 1.24 | 3.89 ± 0. 77 |
| Pioglitazone 10 μM | 4.79 ± 0.60 | No change |
| Pioglitazone 50 μM | 3.30 ± 0.53 | 2.35 ± 0.21 |
| Troglitazone 10 μM | 9.64 ± 6.78 | 2.45 ± 0.20 |
| Troglitazone 50 μM | N.A. | N.A. |
Primary human hepatocytes (n = 3 wells per treatment) were incubated for 48 h with 0.1% DMSO (control) or one of the following positive controls: rifampin (50 μM), dexamethasone (10 μM), or phenobarbital (1 mM) or rosiglitazone or pioglitazone or troglitazone at 10 and 50 μM. At the end of these treatments, the culture medium was discarded, RNA extracted, reverse transcribed, fluorescently labeled, and microarray analysis was conducted as described under Materials and Methods. Values represent -fold increase over control. The data for the 10 μM dose is from one liver and the 50 μM dose from two livers. Each sample was analyzed in quadruplicate and each value represents the mean +/- S.D. Under the conditions used for this set of experiments (Kostrubsky et al., 2000), RNA could not be obtained from troglitazone (50 μM) samples.
N.A., not available.